Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients issues and recommendations

ONCOLOGY

Volumn 23, Issue 1, 2009, Pages 27-34

  Pritchard, Kathleen I ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLADEXA;

ADJUVANT THERAPY; ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; FEMALE FERTILITY; FEMALE INFERTILITY; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUATION; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OVARY FUNCTION; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREMENOPAUSE; PROTEIN EXPRESSION; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; RECURRENCE RISK; REPRODUCTIVE TOXICITY; RISK REDUCTION; SENTINEL LYMPH NODE; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MENOPAUSE, PREMATURE; METHOTREXATE; MIDDLE AGED; OVARIECTOMY; OVARY; PREMENOPAUSE; QUALITY OF LIFE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 61449260033     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107, 1896.
2. Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog Horm Rres 18:387-414, 1962.
3. Canadian Cancer Society: Canadian Cancer Statistics, 2008. Available at www.cancer.ca. Accessed December 1, 2008.
4. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-1692, 1988.
5. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992.
6. Pritchard KI: Ovarian ablation as adjuvant therapy for premenopausal women with early breast cancer: Phoenix arisen? (editorial). Lancet 339:95-96, 1992.
7. Taylor CW, Green S, Dalton WS, et al: Multicentere randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An Intergroup study. J Clin Oncol 16:994-999, 1998.
8. Klijn JR, Blamey F, Boccardo T, et al: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001.
9. Arriagada R, Le MG, Spielmann M, et al: Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16:389-396, 2005.
10. Baum M, Hackshaw A, Houghton J, et al: Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer 42:895-904, 2006.
11. Davidson NE, O'Neill AM, Vukov AM, et al: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol 23:5973-5982, 2005.
12. LHRH-agonists in Early Breast Cancer Overview Group: Use of luteinizing-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomized adjuvant trials. Lancet 369:1711-1723, 2007.
13. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An Overview of the randomized trials. Lancet 365:1687-1717, 2005.
14. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London. Lancet 341:1293-1298, 1993.
15. Engelsman E, Klijn JCM, Rubens RD, et al: Classical CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur J Cancer 27:966-970, 1991.
16. Ejlertsen B, Dombernowski P, Mouridsen HT, et al: Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP) (abstract 248). Proc Am Soc Clin Oncol 18:66a, 1999.
17. Jakesz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in pnemenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group trial J Clin Oncol 20:4621-4627, 2002.
18. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. J Clin Oncol 20:4628-4635, 2002.
19. von Minckwitz G, Graf E, Geberth M, et al: Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients (abstract 534). The GABG IV-A-93 trial. Proc Am Soc Clin Oncol 23:10, 2004.
20. Wallwiener D, Possinger K, Schmid P, et al: A phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal breast cancer patients (abstract 533). Proc Am Soc Clin Oncol 23:10, 2004.
21. Bernhard J, Zahrieh D, Castiglione-Gertsch M, et al: Adjuvant chemotherapy followed by goserelin compared with either modality alone: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients. The International Breast Cancer Study Group Trial VIII. J Clin Oncol 25:263-270, 2007.
22. Roche H, Kerbrat P, Bonneterre J, et al: Complete hormonal, blockade versus chemotherapy in premenopausal early-stage breast cancer patients (pts) with positive hormone receptor (HR+) and 1-3 node-positive (N+) tumor: Results of die FASG 06 trial (abstract 279). Proc Am Soc Clin Oncol 19:72a, 2000.
23. Levine MN, Bramwell VH, Pritchard KI, et al: A randomized trial of cyclophosphamide, epirubicin, fluorouracil chemotherapy compared with cyclophosphamide, methrotrexate, fluorouracil in premenopausal women with node positive breast cancer. J Clin Oncol 16:2651-2658, 1998.
24. Citron M, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versusu conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431-1439, 2003.
25. Burnell M, Levine M, Chapman JA, et al: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paditaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis (abstract A-53). Breast Cancer Res Treat 100(suppl 1), 2006.
26. Pritchard KI: Adjuvant therapy for pre-menopausal women with breast cancer: Is it time for another paradigm shift? J Clin Oncol 20:4611-4614, 2002.
27. Ganz PA, Rowland JH, Desmond K, et al: Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. J Clin Oncol 16:501-514, 1998.
28. Knobf MT: Carrying on: The experience of premature menopause in women with early stage breast cancer. Nurs Res 51:9-17, 2002.
29. Wilmoth M: The aftermath of breast cancer: An altered sexual self. Cancer Nurs 24:278-286, 2001.
30. Dow K, Ferrell BR, Haberman M: The meaning of quality of life in cancer survivorship. Oncol Nurs Forum 26:519-528, 1999.
31. Ganz PA, Greendale GA, Petersen L, et al: Breast cancer in younger women: Reproductive and late health effects of treatment. J Clin Oncol 21:4184-4193, 2003.
32. Goodwin PJ, Ennis M, Pritchard K, et al: Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC) (abstract 8014). Proc Am Soc Clin Oncol 22:728, 2004.
33. Bloom JR, Kessler L: Risk and timing of counseling and support intervention for younger women with breast cancer. JNCI Monogr 16:199-206, 1994.
34. Vinokur A, Threatt B, Vinokur-Kaplan D: The process of recovery from breast cancer for younger and older patients: Changes during the first year. Cancer 65:1242-1254, 1990.
35. Mor V, Malin M, Allen S: Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr 16:191-197, 1994.
36. Spencer S, Lehman J, Wynings C: Concerns about breast cancer and relations to psychosocial well-being in a multiethnic sample of early-stage patients. Health Psychology 18:159-168, 1999.
37. Arora N, Gustafson D, Hawkins R: Impact of surgery and chemotherapy on teh quality of life of younger women with breast carcinoma: A prospective study. Cancer 92:1288-1298, 2001.
38. Kroenke CH, Rosner B, Chen WY, et al: Functional impact of breast cancer by age at diagnosis. J Clin Oncol 22:1849-1856, 2004.
39. Ganz PA, Kwan L, Stanton AL, et al: Quality of life at the end of primary treatment of breast cancer: First results from the Moving Beyond Cancer randomized trial. J Natl Cancer Inst 96:376-387, 2004.
40. Hürny C, Bernhard J, Coates AS, et al: Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347:1279-1284, 1996.
41. Schag CA, Ganz PA, Polinsky ML, et al: Characteristics of women at risk for psychosocial distress in the year after breast cancer. J Clin Oncol 11:783-793, 1993.
42. Carpenter J, Johnson DH, Wagner L, et al: Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 29:E16-E25, 2002.
43. Carpenter J, Elam JL, Ridner SH, et al: Sleep, fatigue and depressive symptoms in breast cancer survivors and matched healthy women experiencing hot flashes. Oncol Nurs Forum 31:591-598, 2004.
44. Couzi RJ, Helzlsouer KJ, Fetting JH: Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13:2737-2744, 1995.
45. Knobf MT: The influence of symptom distress and preparation on responses of women with early stage breast cancer to induced menopause. Psycho-Oncology 8:88a, 1999.
46. Ganz PA, Coscarelli A, Fred C: Breast cancer survivors: Psychosocial concerns and quality of life. Breast Cancer Res Treat 38:183-199, 1996.
47. Ganz PA, Desmond KA, Belin TR, et al: Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 17:2371-2380, 1999.
48. Lindley C, Vasa S, Sawyer WT, et al: Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16:1380-1387, 1998.
49. Dorval M, Maunsell E, Deschenes L, et al: Long-term quality of life after breast cancer: Comparison of 8-year survivors with population controls. J Clin Oncol 16: 487-494, 1998.
50. Ganz PA, Desmond KA, Leedham B, et al: Quality of life in long-term disease-free survivors of breast cancer: A follow-up study. J Natl Cancer Inst 94:39-49, 2002.
51. Barton D, Wilwerding M, Carpenter L, et al: Libido as part of sexuality in female cancer survivors. Oncol Nurs Forum 31:599-607, 2004.
52. Pagani O, O'Neil A, Castiglione M, et al: Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632-640, 1998.
53. Parulekar W, Day AG, Ottaway JA, et al: Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group study - NCIC CTG MA.5. J Clin Oncol 23:6002-6008, 2005.
54. Aebi S, Gelber R, Castiglione-Gertsch M: Is chemotherapy alone adequate for young women with estrogen-receptor-positive breast cancer. Lancet 365:1869-1874, 2000.
55. Averette HE, Boike GM, Jarrell MA: Effects of cancer chemotherapy on gonadal function and reproductive capacity. Cancer J Clin 40:199-209, 1990.
56. Meirow D: Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 169:123-131, 2000.
57. Knobf MT: The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 11:96-110, 2006.
58. Goodwin PJ, Ennis M, Pritchard KI, et al: Risk of menopause during the first year after breast cancer diagnosis J Clin Oncol 17:2365-2370, 1999.
59. Bonadonna G, Valagussa P, Rossi A, et al: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95-115, 1985.
60. Andersson M, Kamby C, Jensen MB, et al: Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial. Eur J Cancer 35:1659-1666, 1999.
61. Castiglione-Gertsch M, Price K, Nasi ML, et al: Is the addition of adjuvant chemotherapy always necessary in node negative postmenopausal breast cancer patients who receive tamoxifen? First results of the IBCSG Trial LX (abstract 281). Proc Am Soc Clin Oncol 19:73A, 2000.
62. Castiglione-Gertsch M, O'Neill A, Gelber RD, et al: Is the addition of adjuvant chemotherapy always necessary in node negative pre/ perimenopausal breast cancer patients who receive goserelin? First results of IBCSG trial VIII (abstract 149). Proc Am Soc Clin Oncol 21:38a, 2002.
63. Boccardo F, Rubagotti A, Amoroso D, et al: Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718-2727, 2000.